Reuters logo
REFILE-Sage Therapeutics postpartum depression drug meets main goal
November 9, 2017 / 11:14 AM / in a month

REFILE-Sage Therapeutics postpartum depression drug meets main goal

(Refiled for typo in first paragraph)

Nov 9 (Reuters) - Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies.

The drug, brexanolone, achieved lower rates of depression in patients compared with a placebo in both trials.

Postpartum depression is a common complication of childbirth that affects about 10 to 20 percent of women giving birth in the United States, the company said. (Reporting by Tamara Mathias in Bengaluru; Editing by Bernard Orr)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below